BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 32820162)

  • 21. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
    Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
    Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
    Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.
    Mehdi A; Riazalhosseini Y
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28812986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
    Liao L; Testa JR; Yang H
    Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
    Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC).
    Ricketts CJ; Linehan WM
    PLoS One; 2015; 10(10):e0140257. PubMed ID: 26484545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients.
    Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Wang Z; Xie H; Dai B; Xu J; Ye D
    Oncotarget; 2017 May; 8(21):35244-35254. PubMed ID: 27806328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths.
    Poehlman WL; Hsieh JJ; Feltus FA
    Sci Rep; 2019 Feb; 9(1):2899. PubMed ID: 30814637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A four-gene signature predicts survival in clear-cell renal-cell carcinoma.
    Dai J; Lu Y; Wang J; Yang L; Han Y; Wang Y; Yan D; Ruan Q; Wang S
    Oncotarget; 2016 Dec; 7(50):82712-82726. PubMed ID: 27779101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
    Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
    J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of PBRM1 expression is associated with renal cell carcinoma progression.
    Pawłowski R; Mühl SM; Sulser T; Krek W; Moch H; Schraml P
    Int J Cancer; 2013 Jan; 132(2):E11-7. PubMed ID: 22949125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.
    Zhou Q; Qi Y; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Xu L; Dai B; Guo J; Zhu Y; Zhang W; Xu J
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32371459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide screening and cohorts validation identifying novel lncRNAs as prognostic biomarkers for clear cell renal cell carcinoma.
    Zhang C; Huang D; Liu A; Xu Y; Na R; Xu D
    J Cell Biochem; 2020 Mar; 121(3):2559-2570. PubMed ID: 31646670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
    Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
    Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
    Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
    Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Array‑based DNA methylation profiling.
    Kim YJ; Jang W; Piao XM; Yoon HY; Byun YJ; Kim JS; Kim SM; Lee SK; Seo SP; Kang HW; Kim WT; Yun SJ; Shon HS; Ryu KH; Kim SW; Ha YS; Yoon GS; Lee SC; Kwon TG; Kim WJ
    Oncol Rep; 2019 Jul; 42(1):453-460. PubMed ID: 31115548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.
    Oike T; Ogiwara H; Nakano T; Yokota J; Kohno T
    Jpn J Clin Oncol; 2013 Sep; 43(9):849-55. PubMed ID: 23904343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.